Clinical trial
Tipifarnib Plus Tamoxifen in Treating Women With Metastatic Breast Cancer
NCT00052728 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00052728 |
|---|---|
| Title | Tipifarnib Plus Tamoxifen in Treating Women With Metastatic Breast Cancer |
| Official title | A Phase II Trial Of Tipifarnib (R15777, ZARNESTRA) In Combination With Tamoxifen In Subjects With Metastatic Breast Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | tamoxifen citrate, tipifarnib |
| Start date | Dec 1, 2002 |
| Completion | Jul 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 19, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: